首页 正文

Financial Feasibility of BPaL(M) Under Pretomanid Price Scenarios - China, 2023-2024

{{output}}
What is already known about this topic?: The BPaL(M) regimen is a World Health Organization (WHO)-endorsed, all-oral, shorter treatment for multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB) recently approved in China; h... ...